Xenon Pharmaceuticals (XENE) Share-based Compensation (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Share-based Compensation data on file, last reported at $16.9 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 38.77% year-over-year to $16.9 million in Q1 2026; TTM through Mar 2026 was $58.4 million, a 1971.14% increase from a year earlier, with the FY2025 full-year figure at $97.5 million, down 2.33% from the prior year.
• Share-based Compensation for Q1 2026 stood at $16.9 million, up from $14.1 million in the prior quarter.
• Over the last five years, Share-based Compensation for XENE reached as high as $16.9 million in Q1 2026 and fell as low as -$37.1 million in Q4 2024.
• Historically, Share-based Compensation has averaged $6.2 million across 5 years, with a median of $9.2 million in 2023.
• Across the five-year window, Share-based Compensation sank 526.8% in 2022 and jumped 179.53% in 2023, its largest moves.
• Year by year, Share-based Compensation stood at -$11.5 million in 2022, then soared by 179.53% to $9.2 million in 2023, then sank by 503.74% to -$37.1 million in 2024, then surged by 138.08% to $14.1 million in 2025, then advanced by 19.69% to $16.9 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $16.9 million in Q1 2026, $14.1 million in Q4 2025, and $13.7 million in Q3 2025.